DLBCL

A study found that glofitamab plus gemcitabine and oxaliplatin significantly improved survival in patients with relapsed/refractory diffuse large B-cell lymphoma who were not eligible for stem cell transplant.

During a Case-Based Roundtable® event, Sairah Ahmed, MD, discussed the data behind the use of lisocabtagene maraleucel for patients with diffuse large B-cell lymphoma in the second article of a 2-part series.

During a Case-Based Roundtable® event, Sairah Ahmed, MD, discussed how the burgeoning use of chimeric antigen receptor T-cell therapy presents a paradigm shift in treatment for patients with diffuse large B-cell lymphoma in the first article of a 2-part series.

During a Case-Based Roundtable® event, Alvaro Jose Alencar, MD, moderated a peer discussion on treatment options for a patient with diffuse large B-cell lymphoma whose disease relapsed eight months after completion of standard R-CHOP.

In separate, live virtual events, Kami J. Maddocks, MD, and Sairah Ahmed, MD, discussed the use of loncastuximab tesirine for a patient with later-line diffuse large B-cell lymphoma.

During a Case-Based Roundtable® event, Haifaa Abdulhaq, MD discussed with participants whether the POLARIX trial influences their choice to use the pola-R-CHP as opposed to R-CHOP regimen for patients with newly diagnosed diffuse large B-cell lymphoma.

During a Case-Based Roundtable® event, Elizabeth A. Brém, MD, discussed treatment approaches for a patient with early relapsed or primary refractory diffuse large B-cell lymphoma in the first article of a 2-part series.

The phase 3 STARGLO trial met its primary end point, improving overall survival in patients with relapsed/refractory diffuse large B-cell lymphoma with glofitamab and chemotherapy vs rituximab and chemotherapy.

During a Case-Based Roundtable® event, Emily Ayers, MD, discussed the long-term results with loncastuximab in patients with diffuse large B-cell lymphoma and how this drug fared in the real-world setting in the second article of a 2-part series.

During a Case-Based Roundtable® event, Emily Ayers, MD, discussed the current landscape for the treatment of patients with diffuse large B-cell lymphoma, the need for better risk stratification data, and what led to the approval of loncastuximab tesirine in the first article of a 2-part series.

Findings from the phase 3 ECHELON-3 trial demonstrated that brentuximab vedotin plus lenalidomide and rituximab led to improvements in overall survival among patients with diffuse large B-cell lymphoma.

Bispecific antibodies are a powerful class of therapy that offer an alternative or complement to CAR T-cell therapies, but there are similar challenges to implementing them in clinical practice. In live events, experts discussed their experience setting up standard operating procedures in their cancer centers.

At a live virtual event, David Rizzieri, MD, CPE, provided commentary on the landscape of treatment for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

In the second part of a 2-article series, Matthew A. Lunning, DO, FACP, leads a discussion on how to best manage toxicities from tafasitamab and lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.

In an interview with Targeted Oncology, Bruce Feinberg, DO, discussed the importance of real-world data, highlighting recent findings on tafasitamab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma in the United States.

In the second part of a 2-article series, Matthew Matasar, MD, MS, discusses long-term follow up data from the LOTIS-2 trial and how these data show the durability and tolerability of loncastuximab for patients with relapsed/refractory diffuse large B-cell lymphoma.

In the first part of a 2-article series, Matthew A. Lunning, DO, FACP, takes into consideration the perspectives of his peers on the use of tafasitamab and lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.

In an interview with Targeted Oncology, Jon E. Arnason, MD, discussed an analysis looking at circulating tumor DNA among patients with follicular lymphoma and diffuse large B-cell lymphoma from the ELM-2 trial.

Findings from a phase 2 study found that treatment with axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma led to a complete metabolic response of 71%.

During a Targeted Oncology™ Case-Based Roundtable™ event, Amitkumar Mehta, MD, discussed what regimens are available for patients who progressed after 2 prior lines of therapy for diffuse large B-cell lymphoma, and what tolerability concerns there are for these regimens.

In the first part of a 2-article series, Matthew Matasar, MD, MS, discusses where loncastuximab fits into the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma and the data that led to the antibody drug conjugate’s approval.

Sabarish Ram Ayyappan, MD, discusses the mechanism of action of odronextamab and highlights the phase 2 ELM-2 trial which evaluated the agent in patients with relapsed/refractory diffuse large B-cell lymphoma.

Combining a CDK9 inhibitor with venetoclax and prednisone led to encouraging responses in patients with lymphoid malignancies in the dose-escalation arm of a phase 1 clinical trial.

During a Targeted Oncology™ Case-Based Roundtable™ event, Paolo Strati, MD, discussed treatment selection and sequencing of loncastuximab in the context of new bispecific T-cell engagers. This is the second of 2 articles based on this event.

A study evaluating healthcare expenses identified lisocabtagene maraleucel as a cost-effective second-line treatment for patients with diffuse large B-cell lymphoma.